Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Revenue (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Revenue for 15 consecutive years, with $243000.0 as the latest value for Q4 2025.

  • Quarterly Revenue rose 60.93% to $243000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $593000.0 through Dec 2025, down 13.3% year-over-year, with the annual reading at $593000.0 for FY2025, 13.18% down from the prior year.
  • Revenue hit $243000.0 in Q4 2025 for Cardiff Oncology, up from $120000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $243000.0 in Q4 2025 to a low of $68000.0 in Q2 2021.
  • Historically, Revenue has averaged $125500.0 across 5 years, with a median of $120500.0 in 2025.
  • Biggest five-year swings in Revenue: surged 146.99% in 2024 and later tumbled 46.83% in 2025.
  • Year by year, Revenue stood at $133000.0 in 2021, then dropped by 3.76% to $128000.0 in 2022, then rose by 21.88% to $156000.0 in 2023, then decreased by 3.21% to $151000.0 in 2024, then skyrocketed by 60.93% to $243000.0 in 2025.
  • Business Quant data shows Revenue for CRDF at $243000.0 in Q4 2025, $120000.0 in Q3 2025, and $121000.0 in Q2 2025.